CLIMB BIO, INC. Deferred Offering Costs
CLIMB BIO, INC. (CLYM) had Deferred Offering Costs of $280.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-06
- 2026-06-30: Deferred Offering Costs $280.00K.
- 2025-06-30: Deferred Offering Costs $0.00.
- 2021-09-30: Deferred Offering Costs $0.00.
- 2021-06-30: Deferred Offering Costs $1.04M.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $280.00K 10-Q · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.04M 10-Q · filed 2021-09-13 |
| 2020-12-31 | $0.00 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |